Treatment of Primary Peritoneal Carcinosis of Digestive Origin Using Cytoreductive Surgery and Hyperthermic Intraoperative Peritoneal Chemotherapy With Mitomycin C and Irinotecan

Inclusion Criteria: * Patients with a peritoneal carcinosis (PC) either of digestive origin or primary: a colorectal or gastric carcinosis, a peritoneal pseudomyxoma or mesothelioma, or a primary carcinosis of the peritoneum regardless the number of prior treatment lines. * A PC and primary tumor considered to be resectable according to preoperative clinical and paraclinical data: absence of mesenteric retraction and absence of bladder invasion. * Patients in good general health (ASA ≤ 2). * Absence of cardiorespiratory failure (PaO2 \> 60 mmHg in a stable condition, dyspnea ≤ NYHA stage 1, left ventricular ejection fraction \> 60%.). * Prothrombin level \>70 %, total bilirubin \< 2 x the normal level, ASAT and ALAT \< 2.5 x normal levels, and alkaline phosphatases \< 5 x normal levels. * Creatinine clearance \> 60 ml/min, polynuclear neutrophils \> 1500/mm3, and a white blood cell count \> 4000 /mm3. * Patients who give written, informed consent. * Patients affiliated with the French universal healthcare system. Exclusion Criteria: * Patients with a PC with ovarian, mammary, biliary, pancreatic, or bronchial origin. * Evolutive patients after systemic chemotherapy. * Patients with a PC considered to be irresectable according to preoperative clinical and paraclinical data: mesenteric retraction or bladder invasion. * Patients in poor general health (ASA \> 2). * Cardiorespiratory failure (dyspnea \> NYHA stage 1, PaO2 \< 60 mmHg in a stable condition) * Prothrombin level \< 70 %. * Any brain abnormality showing on the head scan. * Signs of heart failure and especially left ventricular ejection fraction \< 60% on the cardiac ultrasound. * Thrombocytopenia \< 100 000 / mm3 * Visceral metastases other than a single resectable liver metastasis. * Pregnancy or breast feeding. * Chronic inflammatory intestinal disease and/or an intestinal obstruction. * History of severe hypersensitivity to irinotecan hydrochloride trihydrate or one of the excipients of Campto. * Bilirubinemia \> 3 times the normal upper limit * Yellow fever vaccine. * Prophylactic treatment with phenytoin. * Severe medullary insufficiency.